Aromatase inhibitors (AIs) are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen ...
Treatment strategies after denosumab discontinuation in non-metastatic breast cancer treated with AI
Aromatase inhibitors (AIs) are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen ...
Adding denosumab to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal patients with early-stage, hormone receptor (HR)-positive breast cancer, according to results ...
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated ...
Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States Denosumab is widely used in the treatment of bone metastases ...
From left to right: Dr. Andrea Vethencourt (clinical researcher in the Transformation and Metastasis Group at IDIBELL and the CNIO, and oncologist at ICO); Dr. Eva González-Suarez (leader of the ...
ByEllis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008, 26(30):4875-4882. doi: ...
An international team led by researchers at the Austrian Institute of Molecular Biotechnology (IMBA) in Vienna and the University of Maryland School of Medicine in Baltimore discovered that ...
Three-month romosozumab followed by denosumab is noninferior to a 12-month course for total hip BMD gains in postmenopausal osteoporosis.
On January 19, 2026, Hikma announced the U.S. launch of ENOBY (denosumab-qbde) and XTRENBO (denosumab-qbde)—denosumab biosimilars referencing Amgen’s PROLIA and XGEVA, respectively. As recited in the ...
Credit: Celltrion. The FDA originally approved Stoboclo and Osenvelt as biosimilars in March 2025. The interchangeability designation allows Stoboclo and Osenvelt to be substituted at the pharmacy for ...
Sandoz shared that it has reached agreement with Amgen to resolve all patent disputes between the two companies relating to the Food and Drug Administration approved Sandoz denosumab biosimilars.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results